Tag Archives: Industry

Addiction Medicine Pioneer Dr. A.R. Mohammad Announces Crucial Summit To Discuss FDA Painkiller-Safety Plan With Industry Leaders

August 03, 2012     No comments


Malibu, CA (PRWEB) July 17, 2012

Dr. Akikur Mohammad, Founder of Malibu Horizon, recognized by many as one of the top addiction treatment centers in California, and Assistant Clinical Professor of Psychiatry and the Behavioral Sciences at the University of Southern California, announced today that he and his team will be adding news of the FDA?s recent painkiller-safety plan to the list of topics being discussed during Malibu Horizon?s upcoming educational summit for addiction experts. Unfortunately, the FDA?s plan to deal with painkiller-safety is not what many experts hoped for. While the plan does involve providing mandatory educational courses for physicians about prescription practices, it does not mandate that physicians take the courses, only that the more than 20 companies that produce extended-release painkillers provide grants to make such courses available free or at a nominal cost.

Dr. Mohammad said, ?Frankly, I am saddened and quite disappointed with the FDA?s proposed plan. While it is certainly a step in the right direction, it still doesn?t make prescription education mandatory at a time when heightened physician awareness is mission critical. Instead, the plan simply asks companies that produce certain painkiller manufacturers to underwrite the courses in hopes of attracting more doctors with lower course fees. In my humble opinion, the FDA has failed all of us by taking such a soft approach to solving a problem that has never been this deadly.? Mohammad added, ?While the FDA says that the programs can only be optional for now and simply cannot be mandatory until a new law is passed by Congress, I doubt the intensity with which the FDA is working with the powers that be to effectively and rapidly make the necessary congressional changes.?

Dr. Mohammad and the Malibu Horizon?s team are adding news of the FDA?s recent painkiller-safety plan to the list of topics being discussed during the team?s upcoming educational summit for addiction experts, with the intention of creating a more private sector approach to mandatory physician education. Mohammad added, ?As responsible physicians, it is painfully clear that the onus is on us to take control of the situation. We have the passion and manpower to implement a series education options for both physicians and civilians that we provide privately and monitor publicly. Patients need to know which doctors are working to be better informed and ultimately committed to solving the problem. Would anyone want to put their lives in the hands of a physician who wasn?t staying as informed as possible? Prescription medication is killing more people than ever before and the addiction community must elevate awareness on all fronts before it is too late. We simply don?t have the time to wait for the FDA and Congress to make a change, it must come from within the team on the frontlines.?

For more information about Dr. Akikur Mohammad, alcoholism treatment and Malibu Horizon, visit http://www.malibuhorizon.com.







Find More Alcoholism Press Releases

Read More

Global Bipolar Disorders Market to Reach $5.7 Billion by 2015, According to New Report by Global Industry Analysts, Inc.

August 03, 2012     No comments

San Jose, California (Vocus) June 11, 2010

Bipolar disorder is a chronic and devastating psychiatric disease. Since neither curable nor effectively treatable, the bipolar disorder market is present with significant unmet medical needs. The major drawbacks of existing products include dyskinesis, obsessive-compulsive behavior and psychiatric side effects, as well as ineffectiveness in treating cognitive deficits, rapid recycling or depressive symptoms. In addition, though anti-convulsants (such as Valproic acid) and lithium have considerably enhanced disease prognosis, several patients show poor tolerance to treatment-related side effects. Other major clinical setbacks include lack of compliance to treatment regimen, inadequate clinical response, and relapse.

The United States dominates the world bipolar disorder market as stated by the new market research report on bipolar disorder market. According to the U.S. National Institute of Mental Health, there are about 5.7 million adults aged 18 years and over, suffering from bipolar disorder in the US. The treatment of bipolar disorder differs based on physician specialty in the country. Most psychiatrists follow the recommendations of the American Psychological Association and prescribe lithium, valproic acid and atypical antipsychotics as first-line monotherapies for bipolar mania, and Lamictal as the recommended treatment for bipolar depression. And, unlike the psychiatrists who follow the APA guidelines and prescribe Lamictal first-line, primary care physicians select antidepressants first line.

Bipolar disorder is highly consolidated marketplace with the leading five players accounting for the lion?s share of the market. These players are unlikely to face any major challenge(s) in the future, as pipeline molecules are all targeted at providing only symptomatic relief, and no company is developing any therapy that promises a paradigm shift in the treatment of bipolar disorder. Key players profiled in the report include Abbott Laboratories Inc., AstraZeneca PLC, Bristol-Myers Squibb Company, Cephalon Inc., Dainippon Sumitomo Pharma Co. Ltd., Eli Lilly and Company, Forest Laboratories Inc., Gedeon Richter PLC, GlaxoSmithKline PLC, H. Lundbeck A/S, Janssen Pharmaceutica Inc., Merck & Co., Inc., Otsuka America Pharmaceutical Inc., Pfizer Inc., Repligen Corporation, and Validus Pharmaceuticals Inc.

The report titled ?Bipolar Disorders: A Global Strategic Business Report? announced by Global Industry Analysts Inc., provides a review of unmet medical needs, opportunities and challenges, patent expiries, competitive scenario, select leading products, select pipeline drugs, clinical trials, product approvals/launches, recent industry activity, and coverage on major global market participants. The study analyzes market data and analytics in terms of value sales for regions including The United States, Europe, Asia-Pacific and Rest of World. Global market is analyzed by the following drug classes – Atypical Anti-psychotics and Other Therapeutics.

For more details about this market research report, please visit ?

http://www.strategyr.com/Bipolar_Disorders_Market_Report.asp

About Global Industry Analysts, Inc.

Global Industry Analysts, Inc., (GIA) is a reputed publisher of off-the-shelf market research. Founded in 1987, the company is globally recognized as one of the world?s largest market research publishers. The company employs over 800 people worldwide and publishes more than 1100 full-scale research reports each year. Additionally, the company also offers thousands of smaller research products including company reports, market trend reports, and industry reports encompassing all major industries worldwide.

Global Industry Analysts, Inc.

Telephone 408-528-9966

Fax 408-528-9977

Email press(at)StrategyR(dot)com

Web Site http://www.StrategyR.com/

###







Read More

Medical Marketing Service Inc. Shares Successful Email Marketing Methods That Boost Open Rates by 500% and ROI by 400% at Two Leading Industry Events

August 02, 2012     No comments


Wood Dale, Illinois (PRWEB) July 27, 2012

Medical Marketing Service, Inc. (MMS) recently shared its insights regarding successful email marketing methods that can increase open rates by 500% and ROI by 400% at two leading industry conferences.

EPHARMA WEST

In the wake of the momentous Supreme Court decision affirming the Affordable Care Act, about 100 digital pharma executives gathered for the 3rd Annual ePharma West Summit, which was held July 17-19 in San Francisco.

Email marketing was on the agenda. A presentation by Terry Nugent, EVP Sales and Marketing at MMS, Inc., educated attendees about successful email marketing methods. Nugent outlined what to look for in an email ?messenger?, defined as companies such as MMS that deploy emails, and how to prepare your message so that it succeeds in its objectives. Nugent emphasized the importance of planning, including establishing quantifiable benchmarks that define success, and analyzed the top 10 and bottom 10 pharma marketing emails deployed by MMS in the past 12 months, identifying the characteristics of the successful deployments vs. the unsuccessful. To request a briefing on what it takes to create a top 10 email, contact Terry Nugent at t-nugent(at)mmslists(dot)com or 1.630.477.1553.

Other Summit sessions addressed a wide range of topics from the implications of the Supreme Court health care decision to the impact of segmentation on ROI. For an excellent summary of the proceedings blogged by James Ellis of CloserLook, go to https://workflowy.com/shared/ceb379d8-247f-0b6a-db5c-d33207e3c1d5/#/d6585882-0446-393b-3768-e65f1c4f9bca.

DIGITAL PHARMA WEST

Nugent also spoke at Digital Pharma West, during which the health reform decision news broke. Over 200 digital pharma marketers attended.

Tweets related to email marketing noted the following points:

Think about as designed vs. as rendered. Your beautiful HTML image probably will not viewable to most recipients.

You have to take the time to complete A/B testing before you send email out to all and to test on all devices.

Know your download time of images. Is an HCP going to wait for the image load in their email or delete?

Understand your target list and the types of emails will allow you to understand how the program will succeed.

Webinar emails to HCPs do very well.

Re-email to the segment that is performing best.

Open rate varies based on type of program by specialty.

Email is designed to capture attention at point a, inform and deliver the recipient to point b.

Just in time emailing works — email conference attendees with your key events the night before along with presentations.

Here is a summary of conference highlights, as indicated by the Tweeters at the meeting.

1. Supporting the Physician/Patient Relationship: Leveraging the Digital Platform to Enhance the Opportunity for Dialogue.

The event began with Pre-Conference Workshops, including an excellent seminar entitled ?Supporting the Physician/Patient Relationship: Leveraging the Digital Platform to Enhance the Opportunity for Dialogue.? Co-presenters Scott Tyson of Janssen and Beth Bengston of Hale Advisors gave a masterful overview of how to use digital media strategically. What emerged was a vision of ?Pharma 3.0? in which mobile devices are used to passively monitor patients, feed data into the electronic health record (EHR), trigger healthcare provider (HCP) interventions based on vital signs, and perhaps even adjust health insurance premiums based on therapeutic regimen and lifestyle compliance.

Those tweeting about the presentation noted 94% of EU physicians use smartphones, representing a great email opportunity!

2. Chairperson?s Opening Remarks

In the Chairperson?s opening remarks on Tuesday, June 26th, Sean O?Hagan of Daichi Sankyo cited the following statistics which were noted in tweets:

80% of US Physicians owned smartphones in 2011.

90% use digital resources during the work day

60% of physicians use digital resources during patient consultations;

There has been a 25% drop in sales reps since 2006

42% of offices with 10 or more physicians do not allow access to pharma sales representatives, making multichannel marketing including email crucial to deliver pharma promotional and educational messages.

O?Hagan noted that in today?s world, all marketers are multichannel marketers.

3. Gathering insights from consumers cost-effectively

Lauren Pennington of Pfizer spoke on gathering insights from consumers cost-effectively, generating the following tweets from the delegates:

it is possible to create a great campaign on limited budget
Pharma isn’t facing a marketing problem, it’s facing a marketing opportunity

4. Current ROI Drivers for Multi-Channel Marketing

Janssen?s Tyson made an encore the on Tuesday on a panel answering the question ?What are the Current ROI Drivers for Multi-Channel Marketing?, hosted by Mark Bard of the Digital Care Coalition. He was joined by Kelly Meyers, CEO of Qforma, and Carla Brooks, Regulatory Affairs Senior Manager, Medimmune. Those tweeting about the panel made note of several key points:

Passion and innovation are key attributes of successful digital marketers

The ROI of individual channels is difficult to ascertain, according to Tyson of Janssen, so multichannel campaign ROI must be evaluated holistically rather than by individual tactic;

“ROI” figures are soft; too many steps in the process to directly tie to sales

Be able to explain to regulatory “Why are we doing this?” Regulatory is trying to enable but wants to know what we are trying to accomplish short, medium, long run. We do more damage when we follow the ?build it & they will come? philosophy & then don?t do anything to advance that (argues for using email to promote digital solutions) – Carla Brooks, Medimmune

ROI of medium is wrong question–It’s what you do with it-Scott Tyson, Janssen. Asking the what the ROI of email is would be like asking what the ROI of a pen is – if you use it to scribble, it?s non-existent; if you use it to write the formula for the cure for cancer, it?s astronomical.

Multichannel marketing is an ecosystem of interactions. Look at your audience as a network, not as individuals. Act on the network, not the individual node to create buzz ? Kelly Myers, Qforma

For a recap by Tyler Durbin of GSW?s iQ unit, use this link: http://www.whatsyourdigitaliq.com/current-roi-drivers-for-multi-channel-marketing-digital-pharma-west/

5. The Electronic Health Record

Rich Altus, President of PDR networks noted that approximately 400,000 physicians are using electronic health records (EHRs). About 70% of large practices are using EHRs, so the growth potential is among smaller practices. Not one EHR has more than 60,000 prescribers, according to Altus.

6. Transforming relationship marketing from brand centric to enterprise-wide

Daniel Gandor of Takeda used his musical background to craft a metaphor about orchestrating the transformation of relationship marketing from a disconcerted brand-centric cacophony to an enterprise wide, customer-centric harmonious symphony.

The Twitterati shared the following key points:

Most pharma sites and email are not optimized for mobile even though HCPs are;

Takeda?s Uloric HCP relationship marketing program has 87,000 HCPs registered;

Non personal promo is taking larger role at Takeda — email is the most cost effective tactic;

A robust engagement spectrum keeps the brand in front of the physician;

We’re about to experience a shift in marketing. From a focus on the top line to the bottom line, a shift from reach to ROI.

7. Maximizing prescriber engagement in a mobile world

Epocrates hosted a panel of physicians speaking about maximizing prescriber engagement in a mobile world. Their study on digital omnivores, which found that ?3 screen? HCPs (those that use a PC, smart phone and tablet) spend more time online than single-screen users is available at http://t.co/AWtsuzDb.

One of the most notable observations was that physicians want comparative data about brands. They would have the most respect for a marketer who listed all the brands available in a particular therapeutic class and presented data comparing their product with its competitor on the basis of safety and efficacy and perhaps even cost and thus cost-effectiveness.

Other tweetable moments included:

HCPs want 3 types of content for HCPs: 1 minute, 5 minute or lots of information

Digital omnivores will more than double by Q2 2013

8. Achieving oversize results on modest budgets

Bill Drummy of Heartbeat Digital made an outstanding presentation about achieving oversize results on modest budgets. Using a David vs. Goliath motif. Drummond showed how one of his smallest clients conducted a successful campaign that used patient insights gleaned from mobile to create a breakthrough campaign in the hemophilia market by establishing genuine rapport with sufferers, who refer to themselves as bleeders, by speaking to them in their own language.

Drummy noted that digital campaigns generate up to 29:1 ROI, and that email ROI is very good. He believes that the current opportunity presented by limited budgets will act as a catalyst for adoption of digital marketing in lieu of less cost-effective tactics.

9. Mobile marketing Opportunity in Pharma

The meeting concluded with a daylong workshop on mobile marketing in pharma. Chris Ballentine of Takeda made an excellent presentation highlighting the physician-patient nexus. According to Ballentine, 70% of patients would use an app recommended by their physician, and 9 out of 10 doctors say they want to use apps to help patients manage diseases. This represents an opportunity for pharma to assist HCPs in connecting with their patients. Envision a world in which pharma emails an app link to doctors, and doctors forward it to their patients via email or even Twitter. If such aps could help patients manage diseases less expensively, it would certainly benefit all stakeholders in healthcare: patients, HCPs, and payers. There are regulatory issues. But pharma should certainly take on this challenge to move to a Pharma 3.0 model where the product is not just a pill, it is a solution to the healthcare challenge of the 21st century – achieving better quality AND reducing cost.????

10. See for yourself

All and all, it was a very educational and informative conference. A twitter transcript of the meeting is available at http://hashtags.symplur.com/healthcare-hashtag-transcript.php?hashtag=DigPharm&fdate=06-25-2012&shour=14&smin=13&tdate=06-27-2012&thour=14&tmin=13&ssec=00&tsec=00&img=1

KEEP UP WITH MMS

MMS will be speaking at future industry events on a regular basis. To find out where and when, follow us @mmsemail

ABOUT MMS

Since 1929, Medical Marketing Service, Inc. (MMS), the industry leader in healthcare lists and email marketing, has been pinpointing perfect prospects for clients including pharmaceutical marketers, continuing medical education (CME) providers, publishers, and recruiters, along with the their list brokers, ad agencies and other marketing partners. MMS?s motto is message delivered – we deliver messages to over 1.5 million healthcare professionals (HCPs).

Service is our surname for a reason – personal service by people who care and have decades of experience is the hallmark of our heritage.

Generations of satisfied customers are our legacy, and the foundation of our future – that?s why referrals are our number one source of new customers. We look forward to helping the industry meet the challenges of the 21st century – helping the industry do more with less by achieving maximum return on investment (ROI) with gold standard lists, databases and email marketing services.

MMS was the first Database Licensee of the American Medical Association (AMA), widely recognized as the finest physician database in the world, and guaranteed 99% deliverable for direct mail by MMS. Upon that foundation we have built a selection of lists that maintain that same discerning standard of excellence to reach the entire spectrum of health professionals, featuring lists of the leading healthcare professional associations in each discipline. The results of this decades-long effort to bring you the best available lists and databases are establishment of one source you can rely on for all your healthcare list and email marketing needs.

MMS allows you to reach all the critical healthcare professionals you need to succeed with an integrated, multichannel direct marketing approach that diversifies your campaigns across all media – direct mail, telemarketing, broadcast fax, and email.

For more information, go to http://www.mmslists.com, call 1.800.MED.LIST (633.5478), email sales(at)mmslists(dot)com, and follow us on Twitter @mmsemail.







Find More Cancer Press Releases

Read More

Beer Wholesaling in the US Industry Market Research Report Now Available from IBISWorld

July 27, 2012     No comments


Los Angeles, CA (PRWEB) July 09, 2012

While other wholesalers face the threat of bypass or competition from suppliers that vertically integrate, three-tier distribution laws that require separation between manufacturers and retailers insulate beer distributors. After Prohibition, most states implemented laws that require three distinct levels within the supply chain: producer, wholesaler and retailer. As a result, beer wholesalers have a protected role, and their revenue remains relatively stable through good times and bad, according to IBISWorld industry analyst Agata Kaczanowska. As a middleman serving the Breweries industry (IBISWorld report 31212), the Beer Wholesaling industry is in the mature stage of its life cycle, with a relatively steady profit of about 16.1%.

Role security does not mean that the Beer Wholesaling industry has conducted business as usual since 2007. Changing tides from upstream and downstream industries have reshaped the wholesaling landscape, Kaczanowska says. Beer production has changed rapidly, with more than four-fifths of its market share consolidated into just two companies (AB InBev and MillerCoors), and craft brewery popularity is growing. Meanwhile, changing consumer preferences have created other difficulties for wholesalers. Average consumption stagnated as Americans flocked to wines and cocktails during times of prosperity and shifted spending to cheaper brands during the recession. A recovery in 2012 is expected to stimulate a 0.3% revenue increase, and a combination of the above factors has caused revenue to decline at an average annual rate of 0.5% to $ 57.8 billion over the five years to 2012.

Slowly increasing consumer spending will help the Beer Wholesaling industry’s revenue to gain some momentum during the next five years. IBISWorld projects that revenue will grow during the five years to 2017. Once consumer spending rebounds, prices are expected to increase, facilitating revenue growth. Meanwhile, volumes will remain stagnant as strong demand for regional or microbrews cuts into mainstream sales. Revenue growth and a decline in firm numbers means that surviving firms will be larger and average company earnings will increase. Despite consolidation in this industry, the average industry profit margin is expected to stay steady as producers and retailers continue to squeeze the middleman’s margins. For more information, visit IBISWorld?s Beer Wholesaling in the US industry report page.

Follow IBISWorld on Twitter: https://twitter.com/#!/IBISWorld

Friend IBISWorld on Facebook: http://www.facebook.com/pages/IBISWorld/121347533189

IBISWorld industry Report Key Topics

This industry comprises establishments primarily engaged in purchasing, storing, selling and distributing beer and other fermented malt beverages that are made by the Breweries industry (IBISWorld report 31212).

Industry Performance

Executive Summary

Key External Drivers

Current Performance

Industry Outlook

Industry Life Cycle

Products & Markets

Supply Chain

Products & Services

Major Markets

Globalization & Trade

Business Locations

Competitive Landscape

Market Share Concentration

Key Success Factors

Cost Structure Benchmarks

Barriers to Entry

Major Companies

Operating Conditions

Capital Intensity

Key Statistics

Industry Data

Annual Change

Key Ratios

About IBISWorld Inc.

Recognized as the nation?s most trusted independent source of industry and market research, IBISWorld offers a comprehensive database of unique information and analysis on every US industry. With an extensive online portfolio, valued for its depth and scope, the company equips clients with the insight necessary to make better business decisions. Headquartered in Los Angeles, IBISWorld serves a range of business, professional service and government organizations through more than 10 locations worldwide. For more information, visit http://www.ibisworld.com or call 1-800-330-3772.







Related Alcoholism Press Releases

Read More

Global Irritable Bowel Syndrome (IBS) Therapeutics Market to Reach $1.47 Billion by 2017, According to a New Report by Global Industry Analysts, Inc.

July 24, 2012     No comments

(PRWEB) August 25, 2011

San Jose, California (PRWEB), August 25, 2011 — Irritable Bowel Syndrome, a recurring Gastrointestinal illness, represents an under-penetrated market with a large number of generic drugs presently in use for treating the multiple symptoms. Owing to lack of proper understanding of the disease etiology, the causes, and misdiagnosis of symptoms, only countable number of drugs is presently available in the market for treating more than one symptom associated with IBS. However, over the years, the market has witnessed several improvements, such as the establishment of well-defined diagnostic criteria, exploring novel therapeutic drug classes, emergence of alternative medicines and therapies, in addition to the growing awareness about the chronic nature of the disease.

The global market for Irritable Bowel Syndrome (IBS) therapeutics is presently underserved with a high degree of fragmentation due to the non-availability of a single drug for treating all symptoms associated with this chronic illness. Further, upon considering the diagnostic scenario, nearly 70% of the cases remain undiagnosed while the disease prevalence is quite high. During the initial onset of the disease, patients prefer self-medication based upon their symptoms and rely upon OTC products. The prescription market for IBS comprises of a very few approved drugs for addressing more than one symptom, which show only sub optimal efficacy, and in some cases result in adverse side effects. Physicians prescribe multiple drugs that are not adequate for subsiding the pain, discomfort, and other IBS symptoms. The approval and subsequent release of safe and effective medicines for IBS treatment in the near future is expected to result in substantial growth of the IBS market owing to the premium pricing of these drugs upon release.

The US represents the largest market for irritable bowel syndrome (IBS) therapeutics worldwide, as stated by the new market research report on Irritable Bowel Syndrome Therapeutics. Europe represents the second largest market for IBS therapeutics. Rest of World is projected to emerge as the fastest growing market for IBS therapeutics, exhibiting a CAGR of more than 12% over the analysis period.

The high prevalence and anticipated launch of new drugs in the developed markets during and post 2012 is expected to drive the growth of the IBS market in the coming years. Lotronex (2000) and Amitiza (2008) are the only drugs presently approved for the treatment of Diarrhea Predominant IBS (IBS-D) and Constipation Predominant IBS (IBS-C), respectively. Post US FDA approval and market release in February 2000, Lotronex was withdrawn from the US market in December 2000 owing to safety concerns over this drug. Lotronex was re-launched in 2005, although with a warning label, for restricted use in patients in whom the risk to benefit ratio is balanced. The re-launch of the drug despite the risk associated with its use reflects the high unmet need existing in the IBS therapeutics market. Amitiza, approved for the treatment of IBS-C, is associated with adverse events and side effects. The drug?s safety profile limits the drug?s market size despite its efficacy.

The late stage drug pipeline of Irritable Bowel Syndrome comprises of drug candidates with novel mechanisms of action, and do not belong to the 5HT class of drugs which dominated the drug-development pipeline for the past several years. Despite the efficacy, 5HT class of drugs lack gut-selectivity acting on receptors present in the gut as well as the brain, which is the primary reason for the side effects associated with their use. New drugs in the late stage IBS pipeline, including Linaclotide, Asimadoline, and Dexloxiglumide, exhibit novel modes of action and have demonstrated positive results in terms of safety and efficacy in their respective late stage clinical trials, which makes them promising candidates in the field of IBS treatment. Moreover, each of these is found to be effective in treating a particular IBS-subtype, and not just a single symptom associated with IBS, in respective clinical studies.

Major players profiled in the report include Abbott Laboratories, Edusa Pharmaceuticals, Ironwood Pharmaceuticals Inc., Forest Laboratories Inc., Lexicon Pharmaceuticals, Ocera Therapeutics Inc., Pharmos Corporation, Sucampo Pharmaceuticals Inc., Tioga Pharmaceuticals Inc., among others.

The research report titled ?Irritable Bowel Syndrome (IBS) Therapeutics: A Global Strategic Business Report? announced by Global Industry Analysts Inc., provides a comprehensive review of the Irritable Bowel Syndrome (IBS) market, the disease prevalence, classification, causes, diagnosis, current treatment scenario, select treatments and therapies along with side effects, product approvals in the past, clinical trials, early and late stage pipeline, recent industry activity, product innovations, and profiles of major/niche global market participants. The report provides annual value sales estimates and projections for Irritable Bowel Syndrome Therapeutics market for the years 2009 through 2017 for the following geographic regions ? US, Japan, Europe, and Rest of World. Also, a six-year (2003-2008) historic analysis is provided for additional perspective.

For more details about this comprehensive market research report, please visit ? http://www.strategyr.com/Irritable_Bowel_Syndrome_IBS_Therapeutics_Market_Report.asp

About Global Industry Analysts, Inc.

Global Industry Analysts, Inc., (GIA) is a leading publisher of off-the-shelf market research. Founded in 1987, the company currently employs over 800 people worldwide. Annually, GIA publishes more than 1300 full-scale research reports and analyzes 40,000+ market and technology trends while monitoring more than 126,000 Companies worldwide. Serving over 9500 clients in 27 countries, GIA is recognized today, as one of the world’s largest and reputed market research firms.

Global Industry Analysts, Inc.

Telephone: 408-528-9966

Fax: 408-528-9977

Email: press(at)StrategyR(dot)com

Web Site: http://www.StrategyR.com/

###







More Early Onset Press Releases

Read More

Scientific Research by BotaniPharm Results in Patented Process for Goldenseal That May Become New Industry Standard According to NIH

July 23, 2012     No comments


Candler, NC (PRWEB) June 29, 2012

Goldenseal has been referred to as ?God?s gift to mankind,? and rightly so, say Randy and Cindi Beavers. After more than a decade of hard work, starting on a family farm with humble beginnings, Randy and Cindi Beavers are launching eight natural products based on goldenseal through BotaniPharm, LLC. Native Americans used the plant as an anti-infective and remedy for various digestive disorders, such as indigestion and diarrhea. European settlers quickly saw its value and the goldenseal became a mainstay in the arsenal of the 19th- and early 20th-century physicians.

Demand for the plant exploded and by 1915 concern was being expressed for its survival in the wild. Goldenseal?s popularity continued to grow to the point that, by the end of the 20th century, the plant was designated an internationally protected species. Concerned individuals began to seek ways of not only conserving the plant but also producing it in abundance.

The Beavers recognized that goldenseal could be cultivated by other family farmers who increasingly struggled against gigantic corporate farms more focused on profits than people or protecting the Earth for future generations. The realization that organizing a cooperative effort was the best way to preserve goldenseal, their own farm (called Sleepy Hollow), and other family farms led to the formation of BotaniPharm, LLC.

Over the past decade, the Beavers and collaborators from leading universities have worked with the U.S. Department of Agriculture and National Institutes of Health through a series of Small Business Innovation Research (SBIR) awards to discover how to best grow and process goldenseal. One of the most common complaints about all natural products on the market today is associated with a ?trust and reliability issue,? said Robert Lahm, associate professor of entrepreneurship at Western Carolina University?s Center for Entrepreneurship and Innovation. ?Studies have indicated that up to 70 percent of goldenseal products on the market today are contaminated or adulterated,? said Randy Beavers.

The FDA has identified inconsistent formulations, intentional blending of cheaper substitute herbs, and unintentional contamination at any stage from growing to production as the three major problems in the botanical medicines market. Over the past decade, the Beavers and a small army of supporters have worked with USDA and NIH support to discover how to best grow and process goldenseal. Randy and Cindi have worked with farmers, scientists and researchers, marketing and entrepreneurship consultants, and others. ?BotaniPharm?s ground-breaking research, growing, and production techniques have been aimed at resolving these three problems that the FDA has identified,? said Randy Beavers.

Several faculty across the WCU campus have been consulting with BotaniPharm through WCU?s Small Business and Technology Development Center (SBTDC) for the past two years as part of the university?s efforts to promote regional small business and economic development. ?This has been a dream opportunity for various faculty members to use their expertise in a cross-disciplinary effort to help a small businesses grow and create the potential for new jobs,? said WCU?s Lahm. ?Botanical medicines could be the job-driver we?ve been looking for in this area practically forever. The Appalachian region has always had pockets of extreme poverty, and some of the jobs we can create offer opportunities for a range of skill-sets including foragers, farmers, technicians, managers, marketers and scientists.?

ABOUT:

BotaniPharm?s opportunity is to educate the market and join a movement in the dietary supplement industry towards evidence-based medicine. We will continue to be a leader in the scientific research, testing, and development of natural products.

We are committed to three ideals. First, all of our products are both organic and sustainably produced. Wild goldenseal is now so rare that the herb is listed in the Convention on International Trade in Endangered Species of Wild Fauna and Flora. Second, our patented process guarantees consistent potency based on the bioactivity indicators for different bodily functions. Finally, BotaniPharm makes no compromises in the purity of its products. All products are grown and processed by BotainiPharm?s grower-owners ensuring unadulterated products.

Contact:

Randy Beavers

828-828-575-0370

http://www.BotaniPharm.com

ABOUT:

The WCU College of Business? Center for Entrepreneurship and Innovation is designed to serve as a catalyst for the creation of successful entrepreneurial ventures. The center provides educational support for aspiring and current entrepreneurs, and fosters cross campus and inter-institutional collaboration on the inclusion of entrepreneurship theory and practice for all disciplines. Faculty and staff of the center provide expertise to other organizations that work for economic development, including the SBTDC with which it shares offices.

Through its distance and residential undergraduate and distance master?s level degree programs in entrepreneurship, WCU?s center offers practical hands-on education and service-learning activities facilitated by a faculty of experienced entrepreneurs. The center endeavors to provide students with the skills necessary to think creatively, to successfully launch their own businesses, or to work with an employer in launching and growing an entrepreneurial venture.

For more information, contact Dr. Robert Carton, head of WCU?s Department of Entrepreneurship, Sales and Marketing, and Hospitality and Tourism, at 828-227-3984 or rcarton(at)wcu(dot)edu.

# # #







Read More

Global ADME-Toxicology Testing Market to Exceed $10 Billion by 2017, According to a New Report by Global Industry Analysts, Inc.

July 21, 2012     No comments

San Jose, California (PRWEB) August 29, 2011

New drug discovery is increasingly becoming a high cost proposition for pharmaceutical and biotech companies, owing particularly to the high attrition rate due to drug failure at different stages. Development of a new drug costs about $ 1.0 billion and takes, on an average, 7-10 years before reaching commercialization stage. With companies facing major revenue losses owing to patent expirations and demanding regulatory requirements, besides growing cost pressures, there is growing need to reduce fixed costs and adopt flexible cost models. ADME-Tox issues comprise a leading cause for drug failure/attrition during the pre-clinical as well as clinical stage. The increasing number of drug targets and volume of assay points in drug discovery process are necessitating the need for identifying and eliminating potential hits with high ADME and toxicity profiles. Hence ADME/Tox screening has now become essential at early stage drug discovery and development process. In addition, rising drug discovery costs are fostering the adoption of extensive ADME-Tox screenings not only at early stage of drug discovery and development process but also through the entire process.

Pharma companies are focusing efforts on various innovative approaches to enhance and accelerate ADME-Tox assessments. In silico predictive ADME-Tox is growing at a fast clip and is expected to gain further momentum as the technology can drastically reduce the expenditure incurred due to late stage failure of drug compounds owing to poor ADME-Tox properties. The use of computational models in prediction of ADME/Toxicity properties of compounds is also increasing at a rapid rate owing to the fact that these models offer significant benefits in high throughput screening (HTS). Owing to the significant role of transporter proteins, analysis of drug transporters is gradually becoming a part of ADME assessment and is likely to become a part of regulatory standard for new drug applications.

The United States and Europe account for a lion?s share of the global ADME-Toxicology testing market, as stated by the new market research report on ADME-Toxicology Testing. With the US being home to most of the global pharmaceutical giants, the nation corners a major share of new drug discoveries across the world. The US market for In-Vivo Toxicology testing is forecast to exceed US$ 1.0 billion by 2015. Cell-based assays are expected to emerge as a vital technology in in-vitro test methods in toxicity testing, given their role either as a part of a tiered testing scheme or as test batteries in predicting human toxicity endpoints. Growing interest in screening new drug candidates has propelled the manufacturers of cell-based assays to provide reliable and robust solutions for drug discovery. High Throughput/High Content (HTS/HCS) cell-based assays enable the evaluation of several toxicity endpoints, which is expected to enable identification of various aspects associated with the onset of cell stress. This, in turn, aids in predicting specific cytotoxic effects.

While the US is expected to continue its dominant position in global market, developing regions including Asia-Pacific are poised to register the fastest growth. The high growth in these markets is buoyed by government support and increasing number of collaborations between foreign pharma companies and research laboratories in the region. In particular, India and China have rapidly emerged as ?hot spot? for R&D investment. The emergence and success of contract research organizations (CROs) has made outsourcing of various research projects related to new drug development a viable alternative for pharmaceutical companies, particularly for mid-tier and small players with inadequate infrastructure. Increasing emphasis on early stage ADME-Tox screening and prediction during the last decade and a half has resulted in emergence of large number of dedicated ADME-Tox CROs.

ADME-Tox technologies market place includes pharmaceutical and biotech companies with their in-house research teams and contract research organizations (CROs) that provide ADME-Tox screening at contract. Select players profiled in the report include Accelrys, Inc., ACEA Biosciences, Inc., Agilent Technologies, Inc., Albany Molecular Research, Inc., BD Biosciences, Beckman Coulter, Inc., Bio-Rad Laboratories, Inc., Caliper Life Sciences, Inc., Cambridge Cell Networks Ltd, CeeTox, Inc., Cellartis AB, Celsis International Ltd., Cyprotex PLC, Entelos, Inc., Life Technologies Corporation, Molecular Discovery Ltd., MultiCASE, Inc., Noray Bioinformatics S.L., Optivia Biotechnology, Inc., Promega Corporation, Taconic Farms, Inc., Thermo Fisher Scientific, Inc., Xceleron, Inc. among others.

The research report titled ?ADME-Toxicology Testing: A Global Strategic Business Report? announced by Global Industry Analysts Inc., provides a strategic review of the drug discovery and development market, key market trends in ADME-Tox Technologies, recent product launches, strategic corporate initiatives, and profiles of key market participants. The report provides annual expenditure on ADME-Tox Technologies by the following geographic markets – US, Canada, Japan, Europe and Rest of World. Segments analyzed include Toxicology (In-Vivo and In-Vitro) and ADME.

For more details about this comprehensive market research report, please visit ? http://www.strategyr.com/ADME_Toxicology_Testing_Market_Report.asp

About Global Industry Analysts, Inc.

Global Industry Analysts, Inc., (GIA) is a leading publisher of off-the-shelf market research. Founded in 1987, the company currently employs over 800 people worldwide. Annually, GIA publishes more than 1300 full-scale research reports and analyzes 40,000+ market and technology trends while monitoring more than 126,000 Companies worldwide. Serving over 9500 clients in 27 countries, GIA is recognized today, as one of the world’s largest and reputed market research firms.

Global Industry Analysts, Inc.

Telephone: 408-528-9966

Fax: 408-528-9977

Email: press(at)StrategyR(dot)com

Web Site: http://www.StrategyR.com/

###







Read More

Rising Incidence and High Relapse Rates Drive the Global Acute Myeloid Leukemia (AML) Therapeutics Market, According to New Report by Global Industry Analysts, Inc.

July 12, 2012     No comments

San Jose, CA (PRWEB) July 06, 2012

Follow us on LinkedIn ? Acute Myeloid Leukemia (AML) is identified as a rapidly progressing disease, associated with the elderly. Presently, approved drugs available for the treatment of AML include chemotherapy drugs such as cytarabine, anthracycline, daunorubicin, and mitoxantrone. These therapies, however, are marred with various negative factors such as low cure rates, major side effects such as neutropenia, and high relapse rates. Although other treatment options, such as bone marrow transplant offers comparatively better result, it is however not an effective option for most of the elderly patients due to its high toxicity and dearth of appropriate donors for the procedure. Therefore, the AML market is presently characterized by high unmet needs in terms of drug safety and efficacy presenting increased opportunities for new drugs with improved safety and efficacy profiles.

Over the years, the acute myeloid leukemia (AML) market has witnessed promising targeted drugs failing clinical trials, leading to the slowing down of growth prospects in the AML therapeutics scenario. Some of the promising targeted agents which have failed to improve outcomes in clinical trials include zosuquidar (P-glycoprotein modulator), sulfonylhydrazine alkylator laromustine, and Mylotarg (gemtuzumab ozogamicin). However, innovative new target agents are under various stages of clinical trials, which are expected to showcase promising results in the years to come. Also, AML therapeutic market, in recent years, has witnessed a surge in research and development activities centered on developing molecular targets, which target cell death (apoptosis) and cell cycling, apart from developing novel agents, which target DNA replication and repair. Other approaches which are being developed include immunotherapy and epigenetic based targeting. However, some of these approaches are still in their nascent stages of development, while others are exhibiting promising outcomes. In the upcoming years, the outcome of AML therapeutics are expected to be geared towards developing treatments which are less toxic and potentially safe for the elderly population, when compared to the traditional drugs.

One of the major drivers for the global AML market is the aging population worldwide. Since the incidence of AML significantly increases in the age group of 50 years and above, the aging population therefore forms a major portion of the population seeking treatment for AML. Strong growth for AML therapeutics emanates from developed regions, which have higher percentage of population in the 65+ age group, when compared to the developing countries. Developed markets, such as Europe, the US, and Japan, therefore account for a significant portion of the AML therapeutics market, when compared to the developing economies. While the present treatment of AML for elderly patients remain unimpressive, future strategies adopted by drug developers however are geared towards developing novel target based agents.

As stated by the new market research report on Acute Myeloid Leukemia Therapeutics, the US represents the largest and the fastest growing regional market worldwide. After the US, Europe forms the second largest market for AML therapeutics. Vidaza from Celgene Corp., and Ceplene from Epicept are the major AML drugs in Europe.

Given the fact that leukemia is a relatively smaller market (accounting for a meager 1% of the total cancer cases), and the development of drug in this area proving to be less lucrative for developers, there has been a dearth of investments in AML market over the years. However, various regulatory authorities such as the US FDA and European Medicines Agency (EMA) have taken up initiatives to incite interest among pharmaceutical companies to develop innovative therapies targeting AML. One such initiative taken by the regulators is awarding of orphan drug status and fast track designations or both for drugs that are being developed for AML. The move is expected to provide the much needed impetus to the market, as developers can reap benefits on investment faster, with drug hitting the markets at a faster pace and also gaining from the exclusivity benefit of the drug for a longer time period. Furthermore, with high relapse rates, the goal of treatment for AML is centered upon developing therapies, which aid in prolonged remission. Also, Stem cell transplantation, which hitherto has limited therapeutic application in AML market, are expected to become much more refined, thereby improving the scope of stem cell transplantation, particularly for use in low-intensity procedure for the elderly.

Major players in the market include Ambit Biosciences Inc., Aprea AB, Astellas Pharma Inc., Astex Pharmaceuticals Inc., Bio-Path Holdings Inc., BioSante Pharmaceuticals Inc., Celator Pharmaceuticals Inc., Celgene Corp., Clavis Pharma ASA, Cyclacel Pharmaceuticals Inc., EpiCept Corp., Genzyme Corp., Lorus Therapeutics Inc., Novartis AG, Onconova Therapeutics Inc., Sunesis Pharmaceuticals Inc., among others.

The research report titled ?Acute Myeloid Leukemia (AML) Therapeutics: A Global Strategic Business Report? announced by Global Industry Analysts Inc., provides a comprehensive review of the AML market, the present treatment options, molecular profile of presently approved drugs, the unmet medical needs, key growth drivers, market challenges, pipeline analysis including late-stage drug pipeline, recent FDA and EMAE approvals, drugs obtaining fast track and orphan drug designations, failed drugs, clinical trials, mergers and acquisitions, other strategic corporate deals, and profiles of major and niche key players globally and across different regions. The report provides annual sales estimates and projections for AML Therapeutics market in US$ Million for the years 2009 through 2017 for the following geographic markets – US, Japan, Europe, and Rest of World.

For more details about this comprehensive market research report, please visit ?

http://www.strategyr.com/Acute_Myeloid_Leukemia_AML_Therapeutics_Market_Report.asp

About Global Industry Analysts, Inc.

Global Industry Analysts, Inc., (GIA) is a leading publisher of off-the-shelf market research. Founded in 1987, the company currently employs over 800 people worldwide. Annually, GIA publishes more than 1300 full-scale research reports and analyzes 40,000+ market and technology trends while monitoring more than 126,000 Companies worldwide. Serving over 9500 clients in 27 countries, GIA is recognized today, as one of the world’s largest and reputed market research firms.

Follow us on LinkedIn

Global Industry Analysts, Inc.

Telephone: 408-528-9966

Fax: 408-528-9977

Email: press(at)StrategyR(dot)com

Web Site: http://www.StrategyR.com/







Read More

Global Anxiety Disorders Market to Reach $5.9 Billion by 2017, According to a New Report by Global Industry Analysts, Inc.

July 08, 2012     No comments

San Jose, CA (Vocus/PRWEB) April 12, 2011

GIA announces the release of a comprehensive global report on Anxiety Disorders market. The global market for anxiety disorders is forecast to reach $ 5.9 billion by the year 2017. Key factors driving market growth include rising stress levels that are further augmented by the recent financial crisis, increasing incidence and prevalence of anxiety disorders, growing aging population globally, existence of significant unmet needs, and the development of novel therapeutics.

Stress is one of the most significant health issues of the twenty-first century, to the extent of being called a global epidemic. Anxiety is a normal reaction to stress, which helps one deal with tense situations in the office, study harder for an exam, or keep focus on an important speech. In general, it helps one cope. But when anxiety becomes an excessive, irrational dread of everyday situations, it turns into a disabling disorder. Anxiety disorders represent the most commonly occurring mental health condition, affecting individuals of all age groups. In the recent years, the number of people suffering from anxiety disorders increased considerably owing to the global financial crisis that resulted in rising unemployment rates, and increasing stress levels. Ever-increasing aging global population is also one of the factors responsible for the rapid increase in sales of central nervous system drugs. Major types of anxiety disorders with high prevalence include Social Anxiety Disorder, Post-Traumatic Stress Disorder, Generalized Anxiety Disorder, Panic Disorder, and Obsessive-Compulsive Disorder.

Anxiety therapy addresses and eliminates specific factors causing the disorder and inhibits their reoccurrence, thereby helping in restoring and maintaining normal health of the affected individuals. The first line of agents used for the treatment of anxiety includes Selective Serotonin Reuptake Inhibitors such as Lexapro (Escitalopram), Paxil (Paroxetine), Zoloft (Sertraline), and Prozac (Fluoxetine). The other medications prescribed consist of GABA analogues, including new antidepressant Remeron (Mirtazapine); and MAOIs including Parnate (Tranylcypromine) or Nardil (Phenelzine), Lyrica (Pregabalin) or Neurontin (Gabapentin). TCAs, including Imipramine; atypical anti-psychotics including Quetiapine; and Piperazines including hydroxyzine, are also used for the treatment of anxiety. However, these medications are known to cause various side effects and complications.

Despite being the foundation for pharmacological treatment pertaining to anxiety disorders, the response rate of serotonergic-based treatment is more often below the robust level. In addition, though an array of treatment options are available for treating anxiety disorders, about one-third of patients suffering from psychiatric conditions still do not respond to the drugs that are presently available in the market. There exists an ever-increasing need for developing medications that offer a faster onset of action as compared to the presently available drugs. The research projects being undertaken by companies partly focus on the conventional mode of action, such as adjustment of nor-adrenaline and serotonin levels in the brain, and partly on unique and new mechanism. Physicians are looking at novel drugs for the treatment of anxiety disorders.

The existence of Neurokinin (NK) receptor antagonists, along with Corticotrophin Releasing Factor (CRF) antagonists within the anxiety disorders pipeline, drew major interest from key market participants. The NK receptor antagonists are expected to emerge as promising drugs for the treatment of anxiety disorders. Further, the market is expected to witness a transformation, with anti-psychotic drugs expected to change the future landscape of the anxiety disorder drugs market. Manufacturers of antidepressants are expected to enhance their products’ target patient potential, considering the higher co-morbidity between depression and anxiety.

The US represents the largest regional market for anxiety disorder therapeutics worldwide, as stated by the new market research report on Anxiety Disorders. The US registers the highest number of anxiety disorder cases annually. The country incurs a cost of over US$ 42 million per annum for anxiety disorders, which accounts for almost one-third of the overall cost for mental illnesses. About 27% of the European population suffers from brain disorders, with depression being the most prevalent health problem in several EU-Member States. However, Asia-Pacific is forecast to register the fastest growth during the analysis period, registering a compounded annual growth rate of more than 5.0% during 2009-2017.

Major players profiled in the report include AstraZeneca Plc., Boehringer Ingelheim GmbH, Bristol-Myers Squibb Company, Eli Lilly and Company, F. Hoffmann-La Roche Ltd., Forest Laboratories, Inc., GlaxoSmithKline Plc, H. Lundbeck A/S, Mylan Inc., Neurocrine Biosciences, Inc., Pfizer Inc., Ratiopharm, Sanofi-Aventis, Valeant Pharmaceuticals, Watson Laboratories, among others.

The research report titled ?Anxiety Disorders: A Global Strategic Business Report? announced by Global Industry Analysts Inc., provides a comprehensive review of the anxiety disorders therapeutics markets, current market trends, key growth drivers, leading drugs in the market, overview of pipeline drugs, recent product approvals/launches, recent industry activity, and profiles of major/niche global as well as regional market participants. The report provides annual sales estimates and projections for anxiety disorders therapeutics market for the years 2009 through 2017 for the following geographic markets – US, Europe, Asia-Pacific, and Rest of World. Also, a six-year (2003-2008) historic analysis is provided for additional perspective.

For more details about this comprehensive market research report, please visit ? http://www.strategyr.com/Anxiety_Disorders_Market_Report.asp

About Global Industry Analysts, Inc.

Global Industry Analysts, Inc., (GIA) is a reputed publisher of off-the-shelf market research. Founded in 1987, the company is globally recognized as one of the world?s largest market research publishers. The company employs over 800 people worldwide and publishes more than 1200 full-scale research reports each year. Additionally, the company also offers thousands of smaller research products including company reports, market trend reports, and industry reports encompassing all major industries worldwide.

Global Industry Analysts, Inc.

Telephone: 408-528-9966

Fax: 408-528-9977

E-mail: press(at)StrategyR(dot)com

Web Site: http://www.StrategyR.com/

# # #







Read More

The Business and Industry STEM Education Coalition (BISEC) and Entertainment Industries Council, Inc. (EIC) Team to Announce a Jobs Social Network: SETforJOBS.org

July 07, 2012     No comments


Washington, D.C. (PRWEB) June 22, 2012

SETforJOBS.org is a multimedia site, created by leading industries and key associations of the Business and Industry STEM Education Coalition (BISEC). This unique site features video segments, including Real People, Real Stories, photos, articles, interactive activities, contests, educational tools and more. This site is unlike any other ever created for science, engineering, technology and mathematics because it is a free-form, social networking community that allows members to discuss topics and events, share ideas and even engage in mentoring with national, local and state participants.

?Together, we can foster growth in the workplace and further the cultural shift to inspire Americans, especially young people, to better understand science, engineering, technology and all that creative problem solvers have to offer,? said Ed Swallow, Northrop Grumman Corporation VP, Business Development. ?BISEC and EIC encourage all those who have an interest in science, engineering and technology to take a pledge to support these industries to ensure and enhance our nation?s global economic and workforce status,? Swallow continued.

?The aerospace industry is a leader in innovation and game-changing technology,? said Rick Stephens, Senior Vice President of Human Resources and Administration for The Boeing Company. ?Future competitiveness relies on access to a highly skilled and educated workforce. Our goal is to enhance and elevate interest in science, technology, engineering and mathematics to best prepare students for high-tech jobs of today and tomorrow.?

?One of the best ways to reach young people is through entertainment media, that?s why

EIC became a part of BISEC and is proud to help create this opportunity for community-building and workforce inspiration. The creative community must rally around this national imperative to encourage the pursuit of science, engineering, technology and mathematics careers by making these topics accessible, entertaining and engaging to audiences plus frequently reporting progress in the news. SETforJOBS.org is a paramount tool in our quest to engage and further this attitude and behavior shift,? said Brian Dyak, President and CEO, Entertainment Industries Council, Inc.

The social network is designed to bring professionals, educators, students and others together to share thoughts, ideas, opportunities and STEM advancement that support workforce development and jobs. Currently, members can nominate their favorite show for the Science, Engineering and Technology Awards and enter a contest that could win them a trip to LA for the ceremony! This is just one example of the great discussions ongoing RIGHT NOW!

?SETforJOBS.org and leadership of Entertainment Industries Council are awesome! STEMconnector.org is proud of our partnership. We commend you for the launch of the SETforJobs.org and the massive potential for a special resource based social network. You inspire and give clear messages and resources. STEMconnector with its 4000 plus organization profiles, STEMdaily, STEM Town Halls, 100 Women Leaders in STEM and our mutual desire for network for results, driving communications and metrics to show STEM education progress. Our team is so supportive and proud of the partnership,? commented Edie Fraser, CEO, STEMconnector.

About BISEC

The Business and Industry Stem Education Coalition?s purpose is to enhance and elevate the U.S. commitment to science, technology, engineering and mathematics, and to facilitate STEM Education through private and public partnerships. BISEC?s purpose is also to align efforts to improve STEM education to develop the future workforce in order to build our nation?s economic competiveness, sustain national security, and develop future jobs and employment specialties that engage a dynamic STEM workforce.

About Entertainment Industries Council

EIC, a non-profit organization, was founded in 1983 by leaders of the entertainment industry to bring the power and influence of the industry to bear on communication about health and social issues. The organization is considered to be the chief pioneer of entertainment outreach and one of the premiere success stories in the field of entertainment education. EIC provides information resources for entertainment creators through innovative and time-proven services and methods of “encouraging the art of making a difference” from within the entertainment industry. EIC produces the simulcast national television special PRISM Awards Showcase which addresses accurate portrayals of prevention, treatment and recovery from drug, alcohol and tobacco use, and mental health concerns. The organization also produces the S.E.T Awards, honoring positive and non-stereotypical portrayals of science, engineering and technology. EIC?s web site is http://www.eiconline.org.







Read More
« Older posts
Powered by WordPress | Designed by: best suv | Thanks to toyota suv, infiniti suv and lexus suv